The Emerging Roles of Metabolic Reprogramming in Non-Small Cell Lung Cancer Progression

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Lung cancer is a leading cause of cancer mortality, often characterized by metastasis and treatment resistance.
• Current therapies for advanced non-small cell lung cancer (NSCLC) face challenges due to acquired resistance mechanisms.
• Metabolic reprogramming is increasingly recognized as a key driver of NSCLC progression and survival.

Purpose of the Study:

• To review recent advances in understanding metabolic reprogramming in NSCLC.
• To highlight the role of metabolic heterogeneity and adaptation in NSCLC progression.
• To discuss the challenges and future directions for targeting metabolic pathways in NSCLC treatment.

Main Methods:

• Literature review of preclinical and clinical studies on NSCLC metabolism.
• Analysis of oncogenic mutations and their influence on metabolic pathways in NSCLC.
• Examination of metabolic crosstalk between NSCLC cells and their microenvironment.

Main Results:

• NSCLC cells display heterogeneous metabolic pathway activation influenced by oncogenic mutations.
• Metabolic phenotypes of NSCLC cells evolve under environmental and therapeutic pressures.
• Metabolic adaptations are observed at both primary and metastatic sites, facilitating survival and crosstalk with the microenvironment.

Conclusions:

• Targeting metabolic pathways holds promise for NSCLC treatment, but challenges remain.
• Many targeted metabolic therapies have failed in clinical trials due to off-target effects on normal cells.
• Future research should focus on developing strategies that selectively target cancer-specific metabolic vulnerabilities in NSCLC.